Another study, which included patients with lung cancer harboring KRAS mutations in advanced stages, reported that those with KRAS G12C mutation appeared to have longer progression-free survival after undergoing first-line chemotherapy.[13] A cohort in the United States suggested that none of the KRAS subtypes impact survival, though a positive PD-L1 status revealed a worse outcome in patients with KRAS G12C mutation.[12] In our study, there were no survival differences across the KRAS mutation subtypes (Fig. 2 and Table 4). This evidence concerns the gene KRAS and lung cancer.